Europe Biomarkers Market, By Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarker), Product (Consumables, Services, Software, Growth Hormone Therapy), Mechanism (Genetic, Epigenetic, Proteomic, Lipidomic, and Other Mechanisms), Application (Diagnostics Development, Drug Discovery and Development, Personalized Medicine, Disease Risk Assessment, Others), Disease Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Others) – Industry Trends and Forecast to 2029
Europe Biomarkers Market Analysis and Size
A biomarker is a biological molecule or gene that is utilised to evaluate pharmaceutical reactions, pathogenic procedures, and biological processes effectively and precisely. Biomarkers are molecules found in blood, other bodily fluids, and tissue. They are also known as molecular markers or signature molecules. Biomarkers are commonly used to assess the body's response to a certain treatment for a disease or condition. They help medical professionals make better clinical decisions and diagnosis patients' health. The use of biomarkers as surrogate end-points in the therapeutic development process has been approved by the US Food and Drug Administration (FDA).
Data Bridge Market Research analyses that the biomarkers market which was USD 12.4 billion in 2021, would rocket up to USD 34.39 billion by 2029, and is expected to undergo a CAGR of 13.6% during the forecast period 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Biomarkers (also referred to as signature molecule or molecular marker) are basically utilized to check how the body responds to a treatment of any condition or disease and assist in examining organ functions and other health conditions. These play a vital role in imaging technology to provide clear imaging of oncology tumors and other problems.
Europe Biomarkers Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2019 - 2014)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarker), Product (Consumables, Services, Software, Growth Hormone Therapy), Mechanism (Genetic, Epigenetic, Proteomic, Lipidomic, and Other Mechanisms), Application (Diagnostics Development, Drug Discovery and Development, Personalized Medicine, Disease Risk Assessment, Others), Disease Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Others)
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
Market Players Covered
F. Hoffmann-La Roche Ltd. (U.S), Thermo Fisher Scientific Inc. (U.S) , Abbott (U.S), QIAGEN (Germany), PerkinElmer, Inc. (U.S), Merck KGaA (Germany ) , Bio-Rad Laboratories, Inc. (U.S) , Enzo Biochem, Inc. (U.S) , Charles River Laboratories International, Inc. (U.S), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (U.S), Bruker (U.S), Siemens (U.S), Epigenomics AG (Germany), General Electric (U.S)
Biomarkers Market Dynamics
- Increasing number of patients with rising population
The rising need for non-invasive cancer diagnostics is one of the major factors propelling the biomarkers market forward. Furthermore, the rising number of cancer patients and research programmes and the rise in unhealthy lifestyles and chronic diseases like cardiovascular problems and diabetes all contribute to the market's overall growth.
- Increasing number of CROs
The low cost of clinical trials in emerging countries, the increasing prevalence of cancer, and new research initiatives are expected to accelerate the biomarkers market's growth during the forecast period. The use of minimally invasive techniques for the identification of conditions such as cancer, on the other hand, represents an opportunity that will start the germination of the biomarkers market in the forecast period 2022 to 2029.
- Growing importance of companion diagnostics
The biomarkers market is expected to rise due to reasons such as rising cancer prevalence worldwide, increased finances and grants for biomarker research, and continual product improvements.
Governments are also promoting biomarker technologies across Europe, which are boosting financing for biomarker research. As a result, increased R&D activities are likely to boost the European biomarker technologies market forward in the approaching years. Furthermore, the increasing use of biomarker technologies in drug development and genome mapping studies and a growing inclination for tailored medications are driving the European biomarker technologies market.
However, obstacles such as high investment requirements, high treatment costs, and expensive capital expenditure on equipment are expected to stymie market expansion, as are technical challenges with sample collection and a lack of suitable reimbursement.
This biomarkers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Biomarkers Market
The COVID-19 outbreak caused widespread disruption in nearly every industry. In its realm, the healthcare sector also saw an unparalleled influence. However, this is not the case in the biomarker industry, as biomarkers are critical in developing chronic-care medicines, where the government and pharmaceutical firms will invest heavily, stifling market growth. Various studies have been undertaken, and biomarkers have been discovered to have an important role in diagnosing and treating COVID-19.
In February 2022, Abbott Laboratories released Lingo, a consumer bio wearable that can track important body signals and help consumers better understand and improve their overall health. It could allow biohackers to use a continuous stream of data rather than periodic finger-prick tests, urine samples, and breath readings.
OncoDNA, a genomic and prognostic business, released the OncoDEEP kit in February 2022. The kit provides a complete workflow solution that allows laboratories with NGS capabilities to undertake thorough biomarker testing, perform advanced data analysis, and assist oncologists in providing the most effective and customized cancer treatments for their patients.
Europe Biomarkers Market Scope
The biomarkers market is segmented on the basis of type, product, disease indication, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Safety Biomarkers
- Efficacy Biomarkers
- Predictive Biomarkers
- Surrogate Biomarkers
- Pharmacodynamics Biomarkers
- Prognostic Biomarkers
- Validation Biomarkers
- Drug Discovery and Development
- Personalized Medicine
- Disease Risk Assessment
- Other Applications
- Cancer by Test Type
- Solid biopsy
- Liquid Biopsy
- Infectious Diseases
- Immune Disorders
- Neurological Disorders
- Cardiovascular Disorders
- Other Disease Indications
Biomarkers Market Regional Analysis/Insights
The biomarkers market is analysed and market size insights and trends are provided by country, type, product, disease indication, application and end-user as referenced above.
The countries covered in the biomarkers market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Germany is dominating the market due to the availability of a high-quality healthcare system and a high cancer prevalence rate in the country.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The biomarkers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the biomarkers market. The data is available for historic period 2010-2020.
Competitive Landscape and Biomarkers Market Share Analysis
The biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to biomarkers market.
Some of the major players operating in the biomarkers market are:
- F. Hoffmann-La Roche Ltd. (U.S)
- Thermo Fisher Scientific Inc. (U.S)
- Abbott (U.S)
- QIAGEN (Germany)
- PerkinElmer, Inc. (U.S)
- Merck KGaA (Germany )
- Bio-Rad Laboratories, Inc. (U.S)
- Enzo Biochem, Inc. (U.S)
- Charles River Laboratories International, Inc. (U.S)
- Eurofins Scientific (Luxembourg)
- Agilent Technologies, Inc. (U.S)
- Bruker (U.S)
- Siemens (U.S)
- Epigenomics AG (Germany)
- General Electric (U.S)